Table 6.
The pharmacological information of candidate molecular drugs predicted by the DNN-based DTI model in Figure 5 for biomarkers of psoriasis. (+) means overexpression; (−) means low expression in psoriasis.
| STAT3 (+) | |||
|---|---|---|---|
| Drug | Regulation Ability (L1000) |
Sensitivity (PRISM) |
Toxicity (LC50, mol/kg) |
| CCT-018159 | −0.68150 | 0.068573 | 5.187 |
| Mofezolac | −0.34939 | 0.027005 | 5.684 |
| Eliprodil | −2.14303 | −0.00262 | 5.23 |
| Butein | −1.46898 | −0.05445 | 5.776 |
| LY-303511 | −0.57210 | −0.44921 | 5.075 |
| CEBPB (+) | |||
| Drug |
Regulation ability
(L1000) |
Sensitivity
(PRISM) |
Tox
icity
(LC50, mol/kg) |
| Limonin | −3.138645411 | −0.10563 | 6.726 |
| Mofezolac | −0.427841723 | 0.027005 | 5.684 |
| Betulinic-acid | −0.934850574 | −0.10344 | 6.712 |
| Tangeritin | −0.260343373 | −0.00037 | 5.488 |
| SB-415286 | −0.291000009 | 0.011518 | 6.282 |
| ERK1/2 (+) | |||
| Drug |
Regulation ability
(L1000) |
Sensitivity
(PRISM) |
Toxicity
(LC50, mol/kg) |
| Naringin | −0.12728 | 0.132488 | 6.921 |
| Mofezolac | −0.4780038 | 0.027005 | 5.684 |
| Betulinic-acid | −0.65759182 | −0.10344 | 6.712 |
| Quercetin | −0.297982544 | −0.03326 | 5.222 |
| BIBU-1361 | −0.908186227 | 0.155512 | 6.201 |
| NF-kB (+) | |||
| Drug |
Regulation ability
(L1000) |
Sensitivity
(PRISM) |
Toxicity
(LC50, mol/kg) |
| Naringin | −0.12728 | 0.132488 | 6.921 |
| Mofezolac | −1.00891 | 0.027005 | 5.684 |
| Butein | −1.46898 | −0.05445 | 5.776 |
| Ro-04-5595 | −0.2619 | −0.00387 | 5.443 |
| Flavoxate | −0.75315 | 0.107694 | 5.861 |
| FOXO1 (−) | |||
| Drug |
Regulation ability
(L1000) |
Sensitivity
(PRISM) |
Toxicity
(LC50, mol/kg) |
| Naringin | 0.579085 | 0.132488 | 6.921 |
| Mofezolac | 0.748792 | 0.027005 | 5.684 |
| Betulinic-acid | 0.756684 | −0.10344 | 6.712 |
| Penfluridol | 0.892637 | 0.144082 | 6.202 |
| Dexamethasone | 0.763925 | 0.122088 | 5.128 |